Need professional-grade analysis? Visit stockanalysis.com
$8.96B
N/A
N/A
N/A
Vaxcyte Inc (PCVX) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $60.81, up 0.43% from the previous close.
Over the past year, PCVX has traded between a low of $29.00 and a high of $63.04. The stock has gained 76.2% over this period. It is currently 109.7% above its 52-week low.
Vaxcyte Inc has a market capitalization of $8.96B.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Side-by-side comparison against top Healthcare peers.